Charise Battel
Family · Bristol, VANPI 1316368814
Payments from drug & device makers
Across 145 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$661
- AbbVie$608
- AstraZeneca$382
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$257
- Phathom Pharmaceuticals, Inc.$244
- GSK$171
- plus $884 from 22 others
What the payments were for
- Food & beverage$3,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $661 |
| AbbVie | 39 | $608 |
| AstraZeneca | 19 | $382 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $257 |
| Phathom Pharmaceuticals, Inc. | 2 | $244 |
| GSK | 10 | $171 |
| Pfizer | 8 | $137 |
| Exact Sciences | 5 | $110 |
| Novartis | 4 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Bayer | 2 | $42 |
| Abbott | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Amgen | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,207 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 157 | $141,613 |
| MounjaroTirzepatide | 76 | $94,560 |
| OzempicSemaglutide | 82 | $86,486 |
| JardianceEmpagliflozin | 68 | $60,517 |
| JanuviaSitagliptin Phosphate | 58 | $49,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $38,056 |
| RybelsusSemaglutide | 33 | $36,874 |
| LinzessLinaclotide | 29 | $24,375 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $22,590 |
| FarxigaDapagliflozin Propanediol | 23 | $21,111 |
| XareltoRivaroxaban | 20 | $19,463 |
| Repatha SureclickEvolocumab | 13 | $16,944 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $12,771 |
| MyrbetriqMirabegron | 15 | $12,274 |
| SynthroidLevothyroxine Sodium | 140 | $11,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $137 | $141,613157 claims |
| Novo NordiskOzempic, Rybelsus | $661 | $123,360115 claims |
| Lilly USA, LLCMounjaro | $20 | $94,56076 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $22 | $76,454100 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $171 | $50,82775 claims |
| AbbVieLinzess, Synthroid | $608 | $35,494169 claims |
| AstraZenecaFarxiga, Symbicort | $382 | $27,52248 claims |
| Johnson & JohnsonXarelto | $18 | $19,46320 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $12,27415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $45 | $10,13621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.
Other family in Bristol
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.